These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

118 related items for PubMed ID: 9006890

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. The JAK-inhibitor, JAB/SOCS-1 selectively inhibits cytokine-induced, but not v-Src induced JAK-STAT activation.
    Iwamoto T, Senga T, Naito Y, Matsuda S, Miyake Y, Yoshimura A, Hamaguchi M.
    Oncogene; 2000 Sep 28; 19(41):4795-801. PubMed ID: 11032030
    [Abstract] [Full Text] [Related]

  • 4. The role of the growth hormone (GH) receptor and JAK1 and JAK2 kinases in the activation of Stats 1, 3, and 5 by GH.
    Smit LS, Meyer DJ, Billestrup N, Norstedt G, Schwartz J, Carter-Su C.
    Mol Endocrinol; 1996 May 28; 10(5):519-33. PubMed ID: 8732683
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Platelet-derived growth factor (PDGF)-induced activation of signal transducer and activator of transcription (Stat) 5 is mediated by PDGF beta-receptor and is not dependent on c-src, fyn, jak1 or jak2 kinases.
    Paukku K, Valgeirsdóttir S, Saharinen P, Bergman M, Heldin CH, Silvennoinen O.
    Biochem J; 2000 Feb 01; 345 Pt 3(Pt 3):759-66. PubMed ID: 10642538
    [Abstract] [Full Text] [Related]

  • 7. Constitutive activation of Jak2 contributes to proliferation and resistance to apoptosis in NPM/ALK-transformed cells.
    Ruchatz H, Coluccia AM, Stano P, Marchesi E, Gambacorti-Passerini C.
    Exp Hematol; 2003 Apr 01; 31(4):309-15. PubMed ID: 12691918
    [Abstract] [Full Text] [Related]

  • 8. Differential role of Janus family kinases (JAKs) in interferon-gamma-induced lung epithelial ICAM-1 expression: involving protein interactions between JAKs, phospholipase Cgamma, c-Src, and STAT1.
    Chang YJ, Holtzman MJ, Chen CC.
    Mol Pharmacol; 2004 Mar 01; 65(3):589-98. PubMed ID: 14978237
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Cells transformed by ODC, c-Ha-ras and v-src exhibit MAP kinase/Erk-independent constitutive phosphorylation of Sos, Raf and c-Jun activation domain, and reduced PDGF receptor expression.
    Paasinen-Sohns A, Hölttä E.
    Oncogene; 1997 Oct 16; 15(16):1953-66. PubMed ID: 9365242
    [Abstract] [Full Text] [Related]

  • 11. Coactivation of janus tyrosine kinase (Jak)1 positively modulates prolactin-Jak2 signaling in breast cancer: recruitment of ERK and signal transducer and activator of transcription (Stat)3 and enhancement of Akt and Stat5a/b pathways.
    Neilson LM, Zhu J, Xie J, Malabarba MG, Sakamoto K, Wagner KU, Kirken RA, Rui H.
    Mol Endocrinol; 2007 Sep 16; 21(9):2218-32. PubMed ID: 17550976
    [Abstract] [Full Text] [Related]

  • 12. Discovery of JSI-124 (cucurbitacin I), a selective Janus kinase/signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice.
    Blaskovich MA, Sun J, Cantor A, Turkson J, Jove R, Sebti SM.
    Cancer Res; 2003 Mar 15; 63(6):1270-9. PubMed ID: 12649187
    [Abstract] [Full Text] [Related]

  • 13. SH2-B family members differentially regulate JAK family tyrosine kinases.
    O'Brien KB, O'Shea JJ, Carter-Su C.
    J Biol Chem; 2002 Mar 08; 277(10):8673-81. PubMed ID: 11751854
    [Abstract] [Full Text] [Related]

  • 14. Identification of SH2-bbeta as a potent cytoplasmic activator of the tyrosine kinase Janus kinase 2.
    Rui L, Carter-Su C.
    Proc Natl Acad Sci U S A; 1999 Jun 22; 96(13):7172-7. PubMed ID: 10377387
    [Abstract] [Full Text] [Related]

  • 15. Constitutive activation of Jak-2 and Tyk-2 in a v-Src-transformed human gallbladder adenocarcinoma cell line.
    Murakami Y, Nakano S, Niho Y, Hamasaki N, Izuhara K.
    J Cell Physiol; 1998 May 22; 175(2):220-8. PubMed ID: 9525481
    [Abstract] [Full Text] [Related]

  • 16. Constitutive activation of the Janus kinase-STAT pathway in T lymphoma overexpressing the Lck protein tyrosine kinase.
    Yu CL, Jove R, Burakoff SJ.
    J Immunol; 1997 Dec 01; 159(11):5206-10. PubMed ID: 9548458
    [Abstract] [Full Text] [Related]

  • 17. Activation of the protein tyrosine phosphatase SHP2 via the interleukin-6 signal transducing receptor protein gp130 requires tyrosine kinase Jak1 and limits acute-phase protein expression.
    Schaper F, Gendo C, Eck M, Schmitz J, Grimm C, Anhuf D, Kerr IM, Heinrich PC.
    Biochem J; 1998 Nov 01; 335 ( Pt 3)(Pt 3):557-65. PubMed ID: 9794795
    [Abstract] [Full Text] [Related]

  • 18. Simultaneous activation of JAK1 and JAK2 confers IL-3 independent growth on Ba/F3 pro-B cells.
    Huang HM, Lin YL, Chen CH, Chang TW.
    J Cell Biochem; 2005 Oct 01; 96(2):361-75. PubMed ID: 15988755
    [Abstract] [Full Text] [Related]

  • 19. Mechanism of STAT3 activation by insulin-like growth factor I receptor.
    Zong CS, Chan J, Levy DE, Horvath C, Sadowski HB, Wang LH.
    J Biol Chem; 2000 May 19; 275(20):15099-105. PubMed ID: 10747872
    [Abstract] [Full Text] [Related]

  • 20. Activation of YRP kinase by v-Src and protein kinase C-mediated signal transduction pathways.
    Scholz G, Felder MP, Hanafusa H.
    Proc Natl Acad Sci U S A; 1995 Mar 28; 92(7):2592-6. PubMed ID: 7535926
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.